Melatonin and bone-related diseases : an updated mechanistic overview of current evidence and future prospects
© 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation..
PURPOSE: Bone diseases account for an enormous cost burden on health systems. Bone disorders are considered as age-dependent diseases. The aging of world population has encouraged scientists to further explore the most effective preventive modalities and therapeutic strategies to overcome and reduce the high cost of bone disorders. Herein, we review the current evidence of melatonin's therapeutic effects on bone-related diseases.
METHODS: This review summarized evidences from in vitro, in vivo, and clinical studies regarding the effects of melatonin on bone-related diseases, with a focus on the molecular mechanisms. Electronically, Scopus and MEDLINE®/PubMed databases were searched for articles published on melatonin and bone-related diseases from inception to June 2023.
RESULTS: The findings demonstrated that melatonin has beneficial effect in bone- and cartilage-related disorders such as osteoporosis, bone fracture healing, osteoarthritis, and rheumatoid arthritis, in addition to the control of sleep and circadian rhythms.
CONCLUSION: A number of animal and clinical studies have indicated that various biological effects of melatonin may suggest this molecule as an effective therapeutic agent for controlling, diminishing, or suppressing bone-related disorders. Therefore, further clinical studies are required to clarify whether melatonin can be effective in patients with bone-related diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA - 34(2023), 10 vom: 02. Okt., Seite 1677-1701 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bagherifard, Abolfazl [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.09.2023 Date Revised 21.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00198-023-06836-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358948142 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358948142 | ||
| 003 | DE-627 | ||
| 005 | 20231226075827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00198-023-06836-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM358948142 | ||
| 035 | |a (NLM)37393580 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bagherifard, Abolfazl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Melatonin and bone-related diseases |b an updated mechanistic overview of current evidence and future prospects |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.09.2023 | ||
| 500 | |a Date Revised 21.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation. | ||
| 520 | |a PURPOSE: Bone diseases account for an enormous cost burden on health systems. Bone disorders are considered as age-dependent diseases. The aging of world population has encouraged scientists to further explore the most effective preventive modalities and therapeutic strategies to overcome and reduce the high cost of bone disorders. Herein, we review the current evidence of melatonin's therapeutic effects on bone-related diseases | ||
| 520 | |a METHODS: This review summarized evidences from in vitro, in vivo, and clinical studies regarding the effects of melatonin on bone-related diseases, with a focus on the molecular mechanisms. Electronically, Scopus and MEDLINE®/PubMed databases were searched for articles published on melatonin and bone-related diseases from inception to June 2023 | ||
| 520 | |a RESULTS: The findings demonstrated that melatonin has beneficial effect in bone- and cartilage-related disorders such as osteoporosis, bone fracture healing, osteoarthritis, and rheumatoid arthritis, in addition to the control of sleep and circadian rhythms | ||
| 520 | |a CONCLUSION: A number of animal and clinical studies have indicated that various biological effects of melatonin may suggest this molecule as an effective therapeutic agent for controlling, diminishing, or suppressing bone-related disorders. Therefore, further clinical studies are required to clarify whether melatonin can be effective in patients with bone-related diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chondrosarcoma | |
| 650 | 4 | |a Ewing’s sarcoma | |
| 650 | 4 | |a Fibromyalgia | |
| 650 | 4 | |a Giant cell tumor | |
| 650 | 4 | |a Gout | |
| 650 | 4 | |a Melatonin | |
| 650 | 4 | |a Osteoarthritis | |
| 650 | 4 | |a Osteoporosis | |
| 650 | 4 | |a Osteosarcoma | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 7 | |a Melatonin |2 NLM | |
| 650 | 7 | |a JL5DK93RCL |2 NLM | |
| 700 | 1 | |a Hosseinzadeh, Azam |e verfasserin |4 aut | |
| 700 | 1 | |a Koosha, Fereshteh |e verfasserin |4 aut | |
| 700 | 1 | |a Sheibani, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Karimi-Behnagh, Arman |e verfasserin |4 aut | |
| 700 | 1 | |a Reiter, Russel J |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrzadi, Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA |d 1996 |g 34(2023), 10 vom: 02. Okt., Seite 1677-1701 |w (DE-627)NLM013671383 |x 1433-2965 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:10 |g day:02 |g month:10 |g pages:1677-1701 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00198-023-06836-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 10 |b 02 |c 10 |h 1677-1701 | ||